Orchestra BioMed announces new data from AVIM therapy program

Orchestra BioMed (OBIO) announced new data from its AVIM therapy program, presented at the HRX Live 2025 Meeting, in Atlanta, demonstrating that the blood pressure-lowering effects of AVIM therapy may be sustained for years after activation, are reversible with no evidence of rebound hypertension or blood pressure exceeding initial baseline values, and can be restored upon reactivation. These data further support AVIM therapy’s potential role as a controllable, programmable, and durable device-based therapy for uncontrolled hypertension. A group of patients who originally participated in the MODERATO II trial and underwent long-term follow-up for an average of 3.6 years had sustained 24-hour ambulatory systolic blood pressure reductions of 8.9 mmHg. AVIM therapy was turned off for a washout period of seven days. On Day 1, aSBP returned to 133.1 mmHg, consistent with original baseline hypertension. No residual antihypertensive effects or rebound hypertension were observed. Following the seven-day washout period, aSBP was immediately and significantly reduced upon reactivation. Orchestra BioMed and Medtronic (MDT) have a strategic collaboration to develop and commercialize AVIM therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker.